Alzheimer's

Photo

News • For the first time

Similarity between schizophrenia and dementia dicovered

Researchers for the first time compared schizophrenia and frontotemporal dementia, disorders that are both located in the frontal and temporal lobe regions of the brain.

Photo

News • Early dementia detection

Protein sensor detects Alzheimer's up to 17 years in advance

A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity.

Photo

News • Hypothyroidism as risk factor

To fend off dementia, take care of the thyroid

Older people with hypothyroidism, also called underactive thyroid, may be at increased risk of developing dementia.

Photo

News • Thermogenesis

How Alzheimer's (quite literally) fries the brain

Researchers have shown that aggregation of amyloid-beta, one of two key proteins implicated in Alzheimer’s disease, causes cells to overheat and ‘fry like eggs.’

Photo

News • Opening the blood-brain barrier

3D-printed acoustic holograms against Alzheimer's or Parkinson's

A research team in Spain and the US has created 3D-printed acoustic holograms to improve the treatment of diseases like Alzheimer's and Parkinson's, among others.

Photo

News • Alzheimer's assistance

Dementia: 'Storytelling AI' to aid memory recollection

A new type of AI companion is being designed to aid memory recollection, boost confidence and combat depression in people living with Alzheimer’s disease and other types of dementia.

Photo

News • Brain stimulation

Infrared light helmet might aid dementia patients

Researchers at Durham University are working on a new infrared light therapy that might have the potential to help people with dementia. In the approach, people wear a specially adapted helmet which delivers infrared light deep into the brain for six-minutes per treatment. This stimulates mitochondria that generate most of the chemical energy needed to power the biochemical reaction in the…

Photo

News • microRNAs hint at cognitive decline

Researchers find warning signs for dementia in the blood

esearchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the blood that can indicate impending dementia. Their findings, which are presented in the scientific journal “EMBO Molecular Medicine”, are based on human studies and laboratory experiments. Various university hospitals across Germany were also involved in the investigations.

Photo

News • Dementia prevention

‘Blue spot’ in the brain helps detecting Alzheimer’s early

A miniscule area in the brain, known as the locus coeruleus (LC), or blue spot, can help to identify an increased risk of Alzheimer’s disease at a very early stage. The LC is hidden deep in the brainstem and can only be detected with advanced MRI equipment. Heidi Jacobs (Maastricht University/Harvard Medical School) used MRI scans to show that the tau protein can begin to spread in the LC three…

Photo

News • Early diagnosis proteins

Study identifies 15 new biomarkers for pre­-dementia

A study by an international research group identified 15 novel biomarkers that are linked to late-onset dementias. These biomarkers are proteins, which predict cognitive decline and subsequent increased risk of dementia already 20 years before the disease onset. The proteins are related to immune system dysfunction, blood-brain-barrier dysfunction, vascular pathologies, and central insulin…

Photo

News • Medication development platform

Smart biomarkers to find new drugs against brain diseases

Dr. Hayder Amin and Dr. Caghan Kizil from the DZNE’s Dresden site aim to speed up developing drugs against brain diseases through cutting-edge technology. To this end, they are generating an innovative technology platform, termed “i3D-Markers”, based on high-density microelectrode arrays and 3-dimensional networks of human neurons. Compounds to be tested will be dripped onto this setup, and…

Photo

Aducanumab

FDA grants accelerated approval for Alzheimers drug

The U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

Photo

News • Battle for the brain

New Alzheimer's treatment approach targets tau

A new idea for treating Alzheimer’s disease could eradicate the toxic proteins most closely linked to cognitive decline in the places where they do the most damage, a study from researchers at Columbia University Vagelos College of Physicians and Surgeons suggests. The study was published online in Science Translational Medicine.

131 show more articles
Subscribe to Newsletter